Smith & Nephew plc (NYSE:SNN) Position Boosted by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in Smith & Nephew plc (NYSE:SNN) by 31.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,975 shares of the medical equipment provider’s stock after purchasing an additional 718 shares during the quarter. GAMMA Investing LLC’s holdings in Smith & Nephew were worth $73,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in shares of Smith & Nephew by 8.6% in the second quarter. Rhumbline Advisers now owns 10,365 shares of the medical equipment provider’s stock valued at $257,000 after buying an additional 819 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Smith & Nephew by 9.3% in the 2nd quarter. American Century Companies Inc. now owns 119,347 shares of the medical equipment provider’s stock worth $2,957,000 after acquiring an additional 10,156 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Smith & Nephew by 41.0% during the second quarter. Oppenheimer Asset Management Inc. now owns 16,298 shares of the medical equipment provider’s stock worth $404,000 after purchasing an additional 4,743 shares during the period. Inspire Advisors LLC lifted its holdings in shares of Smith & Nephew by 3.0% during the second quarter. Inspire Advisors LLC now owns 22,286 shares of the medical equipment provider’s stock valued at $552,000 after purchasing an additional 639 shares during the last quarter. Finally, Keene & Associates Inc. boosted its position in shares of Smith & Nephew by 13.2% in the 2nd quarter. Keene & Associates Inc. now owns 11,700 shares of the medical equipment provider’s stock valued at $290,000 after purchasing an additional 1,360 shares during the period. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew Trading Down 1.4 %

NYSE SNN opened at $23.97 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. Smith & Nephew plc has a 1-year low of $23.65 and a 1-year high of $31.72. The firm’s fifty day simple moving average is $25.00 and its 200-day simple moving average is $27.77. The company has a market capitalization of $10.48 billion, a PE ratio of 12.23, a price-to-earnings-growth ratio of 1.41 and a beta of 0.84.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Berenberg Bank cut Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, StockNews.com cut shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.